International Journal of Clinical Research

Objective This article analyzes the individualized dosing regimen of meropenem developed using urine drug concentration monitoring, and its clinical application value in patients with Pseudomonas aeruginosa pyelonephritis. Methods This study selected 42 patients with Pseudomonas aeruginosa pyelonephritis admitted to the hospital from November 2024 to February 2026 as the research sample. They were randomly divided into an observation group and a control group using a random number table method, with 21 patients in each group. The control group adopted an empirical dosing regimen of meropenem, which involved intravenous infusion of 1g every 8 hours. The observation group developed an individualized dosing regimen based on the monitoring results of urine drug concentration. This article compares the clinical treatment efficacy, bacteriological treatment results, and the proportion of urine drug concentration reaching the standard between two groups of patients. Results The total clinical effective rate of the observation group was significantly higher than that of the control group, and the difference was statistically significant (P<0.05); The bacteriological efficacy evaluation and urinary drug concentration% fT>MIC compliance rate of the observation group were significantly higher than those of the control group, and the difference was statistically significant (P<0.05). Conclusion The individualized administration plan of meropenem based on the monitoring results of urine drug concentration can significantly improve the treatment effect of patients with Pseudomonas aeruginosa pyelonephritis, accelerate the infection control process, and grassroots hospitals should promote and apply such plans.

Urinary drug concentration monitoring; Meropenem; Individualized drug administration; Pseudomonas aeruginosa; Pyelonephritis